Citigroup maintains Haemonetics at Buy, raises price target to $149 from $123
Citigroup kept its Buy rating on Haemonetics and increased its price target to $149 from $123, citing a 24.2% upside from the Nov 6 close. Recent analyst targets range from $140 to $145.
How this was made
The 30-second read
Why it matters
The upgrade may attract short-term buying interest but lacks a catalyst beyond analyst opinion.
Market read
Analyst target raise provides modest bullish signal for HAEM.
What to watch
No new earnings or contract news; price target change alone may not sustain a rally.
Background
Citigroup's analyst note updates price target based on internal valuation models.
Market effects
May slightly boost healthcare equipment sector sentiment.
Limited to US markets where HAEM trades.
Minimal
Counterpoint
Target raise could be premature if underlying fundamentals remain unchanged.
Key entities
- financial institutionCitigroup
Equity research analyst raising target.
- companyHaemonetics
Medical device manufacturer.
